Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

Maria Di Bartolomeo, Monica Niger, Federica Morano, Salvatore Corallo, Maria Antista, Stefano Tamberi, Sara Lonardi, Samantha Di Donato, Rossana Berardi, Mario Scartozzi, Giovanni Gerardo Cardellino, Francesco Di Costanzo, Lorena Rimassa, Alberto Gianluigi Luporini, Raffaella Longarini, Alberto Zaniboni, Alessandro Bertolini, Gianluca Tommasello, Graziella Pinotti, Giorgio Scagliotti, Giampaolo Tortora, Andrea Bonetti, Andrea Spallanzani, Giovanni Luca Frassinetti, Davide Tassinari, Francesco Giuliani, Saverio Cinieri, Evaristo Maiello, Claudio Verusio, Sergio Bracarda, Vincenzo Catalano, Michele Basso, Libero Ciuffreda, Ferdinando De Vita, Hector Soto Parra, Lorenzo Fornaro, Marta Caporale, Filippo de Braud, and Filippo Pietrantonio

Abstract

Background: Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However, response rates to first-line chemotherapy range from 30 to 50% and disease progression occurs after 4–6 cycles. The optimal duration of first-line therapy is still unknown and its continuation until disease progression represents the standard. However, this strategy is often associated with cumulative toxicity and rapid development of drug resistance. Moreover, only about 40% of AGC pts. are eligible for second-line treatment.

Methods: This is a randomized, open-label, multicenter phase III trial. It aims at assessing whether switch maintenance to ramucirumab plus paclitaxel will extend the progression-free survival (PFS) of subjects with HER-2 negative AGC who have not progressed after 3 months of a first-line therapy with a platinum/fluoropyrimidine regimen (either FOLFOX4, mFOLFOX6 or XELOX). The primary endpoint is to compare Progression-Free Survival (PFS) of patients in ARM A (switch maintenance to ramucirumab and paclitaxel) versus ARM B (continuation of the same first-line therapy with oxaliplatin/fluoropyrimidine). Secondary endpoints are: overall survival, time-to-treatment failure, overall response rate, duration of response, percentage of patients that will receive a second line therapy according to arm treatment, safety, quality of life. Exploratory studies including Next-Generation Sequencing (NGS) in archival tumor tissues are planned in order to identify potential biomarkers of primary resistance and prognosis.

(Continued on next page)
Background  
Gastric cancer (GC) is the 4th most common cancer and the second leading cause of cancer-related death with 700,000 deaths reported annually, with higher incidence rates in Asia, Costa Rica, Peru, and Eastern Europe [1]. The five-year survival rate of gastroesophageal adenocarcinoma is <30% for all stages and <4% for metastatic disease [2, 3]. Systemic chemotherapy is the standard treatment for HER2 negative, advanced gastric or gastroesophageal junction (GEJ) cancers; first-line chemotherapy generally consists of a fluoropyrimidine and a platinum (cisplatin or oxaliplatin) combination regimen [4].

The V325 Phase 3 trial showed that the addition of docetaxel to cisplatin and 5FU combination improved progression free survival (PFS), overall response rate (ORR) with a small improvement in median survival (median 9.2 months and 8.6 months, respectively, p = 0.02), with increased toxicity [5]. Cunningham et al. in a large, multicenter, randomized Phase 3 study evaluated 4 regimens in first line: epirubicin + oxaliplatin + 5-fluorouracil (5-FU) [EOF], epirubicin + cisplatin + capecitabine [ECX], epirubicin + cisplatin + 5-FU [ECF], epirubicin + oxaliplatin + capecitabine [EOX]. No significant differences were observed in terms of response rate or PFS. Overall survival time was significantly longer among patients receiving EOX versus ECF (9.9 months, 9.3 months, 9.9 months, and 11.2 months for ECF, EOF, ECX, and EOX, respectively) [6]. Capecitabine was shown to be non-inferior to fluorouracil in terms of progression-free survival and overall survival [7]. A randomized phase 3 study compared epirubicin, cisplatin and capecitabine (ECX) with 5-FU, 1-leucovorin and irinotecan (FOLFIRI) as first line treatment in patients with advanced gastric or GEJ cancers. Patients were treated until disease progression or unacceptable toxicity. The results demonstrated no differences in response rate, median progression-free survival (PFS), and overall survival (OS) between the two treatments, except for time to treatment failure (TTF) that was significantly longer in FOLFIRI arm (median TTF: 4.24 vs. 5.1 months; p = 0.008). A second line therapy was administered only in 39% of patients treated with FOLFIRI versus 48% of patients treated with ECX. Approximately only 19% of patients received third line treatment [8].

In the past two years two targeted therapies have been approved so far by the FDA in USA and EMA in EU for advanced GC (AGC): Trastuzumab and Ramucirumab. Trastuzumab is a monoclonal antibody targeting a tumor molecular alteration, that is HER2 overexpression/amplification, found in 10–15% of AGC. It has been shown to have survival benefit in combination with cisplatin/fluoropyrimidine for HER2 positive GC [9]. On the other hand, ramucirumab is a human IgG1 monoclonal antibody targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and it is the first biological treatment given as a single drug that has survival benefits in patients with HER2 negative AGC or GEJ adenocarcinoma progressing after first-line chemotherapy. Ramucirumab was approved in many countries for the treatment of AGC refractory to treatment with fluoropyrimidines and platinum (with or without an anthracycline) based on the positive results of two randomized, double-blind, placebo-controlled, phase III studies. In the REGARD trial, patients progressing after first-line therapy with platinum/fluoropyrimidine regimens were treated with ramucirumab versus placebo [10], while in the RAINBOW trial they were given the combination of ramucirumab plus paclitaxel versus placebo plus paclitaxel [11]. These trials reported a median OS (mOS) of 5.2 months vs 3.8 months (hazard ratio [HR] 0.776, 95% CI 0.603–0.998; p = 0.047) and a mOS of 9.6 months vs 7.4 months (HR 0.807, 95% CI 0.678–0.962; p = 0.017), respectively [12]. Of note, treatment with ramucirumab was associated with improved quality of life results and longer time to clinical deterioration in both the REGARD and the RAINBOW studies. As far as adverse events (AEs) are concerned, the REGARD trial reported similar AEs in the two treatment groups, with the exception of a higher incidence of hypertension in the ramucirumab arm. The combination of ramucirumab and paclitaxel, in the RAINBOW trial, resulted in a...
higher incidence of some ≥ G3 adverse events (AEs), such as neutropenia, hypertension and fatigue. Ramucirumab is now considered to be a standard second-line therapy of AGC in many countries.

Additionally, the results of the phase III RAINFALL study were recently published [13]. The objective of the study was to evaluate the benefit, in term of PFS, of ramucirumab in combination with fluoropyrimidine and cisplatin as first line therapy as compared to fluoropyrimidine and cisplatin alone in patients with AGC. The primary endpoint was met, as there was a very modest but statistically significant increase in median PFS for ramucirumab plus chemotherapy versus chemotherapy alone (5.7 vs. 5.4 months; HR 0.753, 95% CI [0.607, 0.935]; p = 0.0106). However, there was no difference in mOS (11.2 vs. 10.7 months; HR 0.962, 95% CI [0.801, 1.156]; p = 0.6757) nor in overall response rate (41.1% vs. 36.4%; p = 0.17) or disease control rate (81.9% vs. 76.5%; p = 0.095). Among randomized patients, only 50% of patients were treated in second line. However the post-progression treatment (ramucirumab as second line therapy) contributed to jeopardize the survival advantage. Based on these disappointing results, ramucirumab will not be pursued for a first-line indication in GC.

In summary, platinum/fluoropyrimidine regimens represent the backbone of first-line chemotherapy for AGC; the addition of a third chemotherapeutic agent was either associated with an increase in toxicity (i.e. docetaxel), or with a not-demonstrated superiority when compared to doublets [14]. Therefore, the use of triplet regimens in the first-line treatment of gastric cancer patients is limited and not standard. Additionally, clinical responses to first-line treatments range from 30% up to 50%, but disease progression occurs after a median of 4–6 cycles of chemotherapy. Only about 40% of the potential trial population is eligible for second-line treatment, whichever the first-line therapy is.

Continuation of first-line chemotherapy until disease progression or unacceptable toxicity is consistent with observations in clinical practice, published international guidelines and phase III clinical trials in AGC [5, 7, 15, 16]. There is currently no approved treatment as maintenance therapy following first-line treatment for gastric cancer. Since standard of care is not yet established in this setting, best supportive care (BSC) or continuation of fluoropyrimidine are accepted after a lead-in chemotherapy with platinum/fluoropyrimidine association.

Recently, switch maintenance for initial treatment of AGC with immunotherapy has already been conducted in the JAVELIN Gastric 100 study, which results are not mature yet [17].

The ARMANI study is designed to define whether switch maintenance with ramucirumab plus paclitaxel will extend PFS of subjects affected by with HER-2 negative AGC who have not progressed after a first-line platinum/fluoropyrimidine regimen, as compared to continuation of first-line chemotherapy.

**Methods**

**Aims**

Primary objective of this study is to compare PFS of subjects who receive switch maintenance therapy with ramucirumab plus paclitaxel (arm A) following a first-line chemotherapy doublet combination versus subjects who receive continuation of first-line chemotherapy until progressive disease, unacceptable toxicity, patient’s withdrawal consent or death (arm B).

Secondary objectives of this trial are to evaluate OS, time-to-treatment failure (TTF), overall response rate (ORR) and duration of response (DOR) of patients who receive switch maintenance (arm A) versus patients who receive continuation therapy (arm B). Additionally, the study will compare the percentage of patients that will receive a second line therapy according to arm treatment and it will evaluate safety (according to CTCAE v 4.03) and quality of life (patients reported outcomes [PRO]).

**Trial design**

The ARMANI trial is an open label, multicenter, phase III randomized study. This is a superiority trial evaluating ramucirumab plus paclitaxel, given as switch maintenance (arm A), versus continuation of first-line chemotherapy (arm B), given as per standard clinical practice, in subjects with unresectable locally advanced or metastatic HER-2 negative gastric or GEJ cancer, without disease progression following 3 months of first-line doublet chemotherapy with fluoropyrimidine (either 5-FU or capecitabine) and oxaliplatin. Patients will be enrolled by their treating investigators and assigned to a treatment arm by 1:1 randomization. Before randomization the patients who receive continuation of first-line chemotherapy doublet combination versus subjects who receive switch maintenance therapy with ramucirumab plus paclitaxel (arm A) following a first-line chemotherapy doublet combination versus subjects who receive continuation of first-line chemotherapy until progressive disease, unacceptable toxicity, patient’s withdrawal consent or death (arm B).

**Study endpoints**

The primary endpoint is PFS, defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first. Descriptive analysis of PFS will be carried out by plotting Kaplan–Meier survival curves, and median survival will be estimated. As typically done for this type of studies, superiority of the experimental treatment arm...
versus the control one will be established if the confidence interval upper margin of PFS difference is inferior to 1.

An additional analysis will be conducted by mean of the Cox proportional hazard regression model, incorporating information on recognized prognostic factors so as to obtained an adjusted estimate of experimental treatment effect. Similar analyses will be conducted on OS.

All efficacy analyses will be primarily based on the intention-to-treat (ITT) population, and further verified on the per-protocol population.

Secondary endpoints are:
- OS, defined as the time from the first day of treatment to the date of death due to any cause. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive.
- Time-to-treatment failure (TTF), defined as the time from the first day of treatment to the first occurrence of progressive disease and/or withdrawal due to adverse events, insufficient therapeutic response, death, lost to follow-up, refusing treatment/being unwilling to cooperate/withdrawing consent.
- Overall response rate (ORR), defined as the percentage of patients achieving complete and partial responses according to RECIST 1.1 criteria. Best overall response is the best response recorded from the start of treatment until disease progression. Complete and partial responses have to be confirmed by two evaluations of the disease.
- Duration of response (DOR), defined as the time from the initial occurrence of documented CR or PR (whichever occurs first) until documented disease progression as determined by RECIST 1.1.
- The percentage of patients that will receive a second line therapy according to arm treatment.
- Safety, assessed through summaries of adverse events graded according to NCI CTCAE 4.03

### Exploratory endpoints
As exploratory endpoints, potential biomarkers and their correlation with outcome measures will be investigated as follows: change in plasma biomarkers, such as circulating cytokines, and their correlation with outcomes (PFS, ORR, and OS); pharmacogenetic studies to find a potential correlation between single nucleotide polymorphisms and ramucirumab-related toxicity and efficacy, chemotherapy-related toxicity, drugs dose intensity and outcomes (PFS, ORR, and OS); tissue biomarkers present at baseline and investigated with next-generation sequencing (NGS). Samples will be stored at Pathology Department of Fondazione IRCCS Istituto Nazionale Tumori.

### Clinical setting
Patients affected by unresectable, locally advanced or metastatic, HER-2 negative adenocarcinoma of the stomach or GEJ can be evaluated for the study. To be considered eligible, patients must have received 3 months of first-line chemotherapy with one of the fluoropyrimidines-and oxaliplatin-based doublet combinations allowed, with radiological evidence of clinical benefit (either complete response/partial response/stable disease [CR/PR/SD] by RECIST v1.1 criteria in case of measurable disease, or absence of progressive disease in case of non-measurable disease). Patients who had received...
adjuvant cisplatin/oxaliplatin plus fluoropyrimidine-based doublet chemotherapy and had recurrence beyond 12 months from its completion are eligible. Other main inclusion criteria are:

- Measurable and/or evaluable disease based on RECIST v1.1
- ECOG PS 0–1
- Adequate hematologic, hepatic, renal and coagulation function
- Available archival tumor tissue for exploratory research

Main exclusion criteria are:

- HER2 positive status, or diagnosis of squamous cell carcinoma.
- Unresolved toxicity greater than or equal to CTCAE Grade 2 attributed to any prior therapies
- Any serious illness or medical condition(s) that could be considered contraindications for any study drugs
- Treatment with any of the following, within the specified time frame, prior to study drug administration:
  - A. major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to randomization.
  - b. Any investigational agent including VEGF or VEGFR-targeted agents within prior 4 weeks.
  - c. Extended field radiation within prior 4 weeks or limited field radiation within prior 2 weeks.

**Treatment**

The acceptable first-line or lead-in chemotherapy for this protocol will be a fluoropyrimidine and oxaliplatin-containing doublet (bi-weekly oxaliplatin and 5-FU [FOLFOX-4 or mFOLFOX-6 regimen]; three-weekly oxaliplatin and capecitabine [XELOX regimen]). In the induction phase, treatment must be continued for up to 4 three-weekly cycles or 6 bi-weekly cycles, or for up to a maximum of 12 weeks.

Subjects with CR/PR/SD after oxaliplatin and fluoropyrimides-based regimen in case of measurable disease, or without progressive disease in case of non-measurable disease, will be randomized in 1:1 ratio between the two treatment arms:

(Arm A) ramucirumab 8 mg/kg on Days 1 and 15 of every 28-day cycle; paclitaxel 80 mg/m² on Days 1, 8, and 15 of every 28-day cycle.

(Arm B): Continuation of the same induction regimen (FOLFOX-4 or mFOLFOX-6 for up to 6 cycles, XELOX for up to 4 cycles), followed by capecitabine or 5-FU alone.

Those on arm A will receive ramucirumab plus paclitaxel until progressive disease, unacceptable toxicity, informed consent withdrawal or patient’s death. In case of permanent discontinuation of paclitaxel due to unacceptable toxicity (particularly cumulative grade > 2 neurotoxicity), treatment with single-agent bi-weekly ramucirumab will be continued until progressive disease, unacceptable toxicity, informed consent withdrawal or patient’s death. In case of permanent discontinuation of ramucirumab due to unacceptable drug-specific toxicity, treatment with weekly paclitaxel will be continued until progressive...
disease, unacceptable toxicity, informed consent withdrawal or patient’s death.

Patients in arm B will receive continuation of the same regimen used as lead-in chemotherapy with the same dosage of the last cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient’s death. Treatment will be further administered for up to 6 bi-weekly cycles in the FOLFOX schedules or for up to 4 three-weekly cycles in the XELOX schedule; then, after a maximum of 24 weeks of treatment (including both lead-in phase and post-randomization treatment), single agent fluoropyrimidines (capecitabine or 5-FU) will be continued until progressive disease, unacceptable toxicity, informed consent withdrawal or patient’s death. In case of oxaliplatin-induced severe and cumulative toxicity, prior to completion of 24-weeks intensive treatment phase, single agent fluoropyrimidine can be given as maintenance. Second-line treatment will be at Investigator’s discretion.

Statistical design
This is a randomized, open-label, multicenter phase III trial. We plan to enroll up to 280 patients, 140 in the control group and 140 in the study group, over a two-year period. The follow up period is estimated to be of 1 year. The sample size is calculated on the basis of a superiority hypothesis of median PFS with ramucirumab plus a paclitaxel as compared to continuation of first-line CT following the randomization after the induction phase of 3 months. Taking into account a median PFS of 7 months observed in the REAL-2 trial, an overall sample size of 280 subjects (140 in the control group and 140 in the study group) achieves 90% power to detect a probability of increase of median PFS after the induction period from 4 months in the control group to 6 months in the experimental group, with a significance level of 0.05 (2-sided). Equal 1:1 allocation ratio by central randomization in the two trial arms is planned, and the patient accrual pattern over time is foreseen to be uniform. Intention-to-treat Population: All patients that are included in the trial by signing the informed consent and assigned a study patient number (randomized patients). Per Protocol Population: Patients will be excluded from the per-protocol analysis if: 1) they did not receive a minimum of 2 cycles of treatment before undergoing the first radiological reassessment, or 2) there were severe violations of protocol inclusion or exclusion criteria (for example: absence of written informed consent, HER-2 positive GC, progressive disease after the last dose of the lead-in chemotherapy).

Demographic and baseline characteristics such as age, sex, race, and baseline disease characteristics will be summarized by treatment arm for the ITT population. Descriptive baseline summaries of continuous data will present mean, standard deviation, median, minimum, and maximum. Descriptive summaries of discrete data will present the category counts as frequencies and percentages.

Descriptive analysis of PFS will be carried out by plotting Kaplan–Meier survival curves, and median survival will be estimated. As typically done for studies of this type, superiority of experimental treatment toward control will be established in case of the confidence interval upper margin of PFS difference will be inferior to 1. An additional analysis will be conducted by mean of the Cox proportional hazard regression model, incorporating information on recognized prognostic factors so as to obtained an adjusted estimate of experimental treatment effect. Similar analyses will be conducted on OS.

All efficacy analyses will be primarily based on the ITT population, and further verified on the per-protocol population.

The analysis of patients’ reported outcome (PRO- assessed using the EORTC QLQ-C30, the EORTC QLQ-OG25 and the EuroQol EQ-5D questionnaires) will be performed according to the EORTC Scoring and Reference Values Manual. All scores and subscales will be assessed through descriptive summary statistics.

For PFS, patients without a date of disease progression will be analyzed as censored observations on the date of last tumor assessment. If no post-baseline tumor assessment is available, PFS will be censored at day 1. For OS, patients who are not reported as being died will be analyzed as censored observations on the date when they were last known to be alive. If no post-baseline data are available, OS will be censored at day 1. Patients not receiving at least one dose of study drug will be excluded from the analysis of safety. Tables of adverse event incidence and individual incidence will be produced according to the primary system-organ class (SOC) and within the category defined in the CTCAE v4.03. The summaries will be overall (severity grades 1–5) and for grade ≥ 3 events. Multiple occurrences of the same event will be counted once at the maximum severity. A complementary analysis of adverse events by severity of event and by relationship to trial treatment will also be performed. The actions taken in terms of treatment discontinuation will be reported. A standard safety analysis with tables and shift tables for laboratory data will be provided.

The Trial Office of Fondazione IRCCS Istituto Nazionale dei Tumori will develop electronic case report form (eCRF) specific for this study. The Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori will be responsible for data management of this study, including quality checking of the data.
Discussion
The optimal duration of systemic first-line chemotherapy for metastatic gastric cancer is unknown. In many trials, chemotherapy was given until progression or limiting toxicity, whereas in other trials treatment was stopped at a pre-defined time. Given the increasing toxicity rate with a prolonged administration of systemic chemotherapy, patients’ quality of life could be negatively affected. Additionally, regardless the strategy of treatment, the PFS does not seem to be affected.

Given the positive results of both randomized trials and reports from clinical experiences [10, 11, 18], ramucirumab either alone or in combination with paclitaxel has proved to be a safe and active option for second line treatment in gastric cancer. Unfortunately, RAINFALL study failed to prove a clinically relevant benefit of a ramucirumab-based regimen in the first-line setting, as compared to chemotherapy doublets [19]. Nevertheless, the early administration of an active, non-cross resistant treatment after the first-line therapy, before disease progression occurs, might prolong the benefit of first-line treatment and could delay clinical deterioration [20–22]. Small phase 2 trials investigated the feasibility of sequential therapy in AGC [20–22], and they showed the potential of sequential therapy in order to prolong therapeutic benefit of first-line, but with the price of cumulative toxicities. Our hypothesis is that the early administration of a safe second-line regimen such as ramucirumab plus paclitaxel may prolong progression-free survival and consequently allow patients to experience a better quality of life.

PFS was chosen as primary endpoint instead of OS because the latter could be influenced by the best second line treatment available after trial for both arms and by the percentage of patients that are in adequate clinical condition for a second line therapy.

Many other maintenance studies, both for metastatic colorectal and lung cancers, have, in fact, PFS as primary endpoint, as it reflects the direct effect of the maintenance therapy on delaying the disease progression and it is not influenced by post progression treatments.

This topic is remarkably relevant in gastric cancer patients, in which only 40% is usually eligible for second-line treatment, independently of the first-line therapy, due to the rapid deterioration of health status after the first disease progression. The early administration of an active second-line treatment could overcome this problem and it may rescue all those subjects that become ineligible for such therapy.

Additionally, as exploratory endpoints, we will investigate several potential efficacy and toxicity biomarkers both in blood and tissue samples.

Therefore, the ARMANI study will help us at defining whether switchmaintenance with ramucirumab plus paclitaxel is a better strategy then continuation of first-line chemotherapy for HER-2 negative AGC who have not progressed after first-line platinum/fluoropyrimidine regimen.

Abbreviation
S-FU: 5-fluorouracil; AEs: adverse events; AGC: advanced gastric cancer; AION: Associazione Italiana Oncologia Medica; ASCO: American Society of Clinical Oncology; BSC: best supportive care; CI: Confidence Interval; CR: Complete Response; CT: chemotherapy; DOR: duration of response; ECF: epirubicin + cisplatin + S-FU; ECOG PS: Eastern Cooperative Oncology Group – performance status; eCRFs: electronic Case Report Forms; ECX: epirubicin + cisplatin + capecitabine; EMA: European Medicines Agency; EOX: epirubicin + oxaliplatin + S-fluorouracil (S-FU); EOX: epirubicin + oxaliplatin + 5-fluorouracil; ESOM: European Society for Medical Oncology; FDA: Food and Drug Administration; FOLFOX: Folinic-acid, 5-fluorouracil, Oxaliplatin; irinotecan; FOLFFOX: Folinic-acid, S-fluorouracil, irinotecan; FDA: Food and Drug Administration; FOLFOX: Folinic-acid, 5-fluorouracil, irinotecan; FOLFIRI: Folinic-acid, 5-fluorouracil, irinotecan; GEJ: gastroesophageal junction cancers; HR: Hazard Ratio; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; NGS: Next-Generation Sequencing; ORR: Overall Response Rate; OS: Overall Survival; PFS: Progression Free Survival; PR: partial response; PRO: patients reported outcomes; RECIST: Response Evaluation Criteria in Solid Tumors; SD: stable disease; TTF: time to treatment failure; VEGFR2: Vascular Endothelial Growth Factor Receptor 2; XELOX: Capecitabine, Oxaliplatin

Acknowledgements
Not applicable.

Funding
The present study is an investigator-driven trial, carried out by participating clinicians, who have the intellectual ownership of the results. The study is sponsored by Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, ITALY, that will provide the economical support for costs related to data management, statistical analysis and the other activities of central and group coordinating centers. Eli Lilly SPA will provide vials of Ramucirumab and partial financial support for study costs. No funds can be provided to ethical committees and single participating centers. The study will be conducted according to the current regulations.

Availability of data and materials
Not applicable.

Protocol version and date and version identifier
Version 1.1, 01 Aug 2016.

Use of copyright protected materials
Not applicable.

Dissemination policy
The trial results will be presented at national and international conferences such as AIOM, ESMO, WORLD ESMO GI, ASCO or ASCO GI. Results will be published in top tier medical oncology journals. All Principal Investigators will be involved in the manuscript writing.

Roles and responsibilities
The Coordinating Center (Fondazione IRCCS Istituto Nazionale Tumori) and the Data Center (Trial Center, Fondazione IRCCS Istituto Nazionale Tumori) will be responsible for: reviewing the protocol; centralizing databases; controlling the quality of the reported data; emitting Data Query Forms; generating study program reports; generating the Statistical Analysis Plan; perform statistical analysis. Furthermore, the Sponsor provides an insurance policy in case patients suffer harm from trial participation. Since the drugs under investigation are well characterised and know to be well tolerated, the investigators assessed that a data monitoring committee (DMC) was not needed.
Authors’ contributions
MDB and FP designed the study; MDB, FP, MN and MC wrote the original protocol. MDB, FP, MN and MC drafted the manuscript. Their affiliation is: Department of Medical Oncology, Fondazione IRCCS Istituto Tumori, via G. Venezian, 1, 20133 Milan, Italy. SC, MA, ST, SL, SOD, RB, MAS, GGC, FDC, LR, AQ, BL, AZ, AB, GT, GS, GT, AB, AS, GLU, DT, FG, SC, EM, CV, SB, VC, MB, LC, FDV, FST, LF, MC and FdB directly provided their contribution, read and approved the final manuscript.

Ethics approval and consent to participate
The study was registered on April 202/016 at EudraCT database (2016–001783-12) and on October 172/016 at Clinicaltrials.gov (NCT02934464) and it is currently ongoing. The trial was approved by the Ethics Committee of the Fondazione IRCCS Istituto Nazionale Tumori di Milano and by local Committees of participating centers. All study participants will provide their written informed consent after careful explanation by their treating investigators. This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. The study will comply with the requirements of the ICH E2A guideline.

All study participants will provide their written informed consent after careful explanation by their treating investigators. Sponsor’s sample Informed Consent Form will be provided to each site. Each Site can modify the template provided, but the Sponsor will review and approve any proposed deviations from the sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the “Consent Forms”) before IRB/EC submission. Regarding specific Informed Consent(s) on exploratory biomarkers, the investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason. All relevant changes to study procedures or new information will be communicated to all relevant parties (investigators, IRBs, trial participants, trial registries, journals, regulators) and patients will be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy).

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in any of the study data sets. Patient medical information obtained by this study is confidential and may only be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law. Data generated by this study must be available for inspection upon request by representatives of the national and local health authorities, Sponsor’s monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

Consent for publication
Not applicable.

Competing interests
MDB: advisor role/speaker bureau for Eli Lilly, Servier; FP: advisory role/speaker bureau for Amgen Inc., Roche, Sanofi, Eli Lilly and Bayer Healthcare; SL: advisory role/speaker bureau for Amgen Inc., Bayer Healthcare, Merck and Eli Lilly, research funding from Amgen Inc. and Merck Serono; ST: advisor role for Eli Lilly, LR: advisory role/speaker bureau for AstraZeneca, Abbvie, Lilly, Bayer, Sintex Med, Italfarmaco, Sanofi, AQuile, Baxter, Ipsen, Exelixis, Amgen, Incyte, Celgene. For the other authors there are no competing interests for this study.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, via G. Venezian, 1, 20133 Milan, Italy. 2Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Ravenna Viale Randi, 5, 48121 Ravenna, Italy. 3Department of Medical Oncology, IOV Istituto Oncologico Veneto, ViaGattamelata, 64, 35128 Padova, PD, Italy. 4Sandro Pitigliani Medical Oncology Department, Nuovo Ospedale di Prato, Via Suor Niccolina Infiermiera, 20, 59100 Prato, Italy. 5Department of Medical Oncology, AOU Ospedali Riuniti Di Ancona, via Corridoni, 11, 60123 Ancona, Italy. 6Department of Medical Oncology, AOU Cagliari, Via Ospedale, 54, 09124 Cagliari, Italy. 7Department of Medical Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330 – 33100, piazzale Santa Maria della misericordia 15, 33100 Udine, Udine, Italy. 8Department of Medical Oncology, AOU Careggi di Firenze, Largo Brambilla, 3, 50134 Florence, Italy. 9Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Via Alessandro Manzoni, 56, 20089 Rozzano, Milan, Italy. 10Department of Medical Oncology, IRCCS Policlinico San Donato, Piazza Edmondo Malan, 2, 20097 San Donato Milanese, MI, Italy. 11Department of Medical Oncology, Ospedale San Gerardo, Via G. B. Pergolesi, 33, 20900 Monza, Italy. 12Department of Medical Oncology, Fondazione Poliambulanza, Via Leonida Bissolati, 57, 25124 Brescia, Italy. 13Department of Medical Oncology, ASST della Valtellina e dell’Alto Lario, Via Stelvio, 25, 23100 Sondrio, Italy. 14Department of Medical Oncology, Ospedale di Cremona, Viale Concordia, 1, 26100 Cremona, Italy. 15Department of Medical Oncology, Ospedale di Circolo e Fondazione Macchi, Viale Luigi Borri, 57, 21100 Varese, Italy. 16Department of Medical Oncology, AOU San Luigi Gonzaga, Regione Gonzele, 10, 10043 Orbassano, Torino, Italy. 17Department of Medical Oncology, AOU Verona Ospedale Policlinico ‘Giambattista Rossi’ di Borgo Roma, Piazzale L.A. Scuro, 10, 37134 Verona, VR, Italy. 18Department of Medical Oncology, Ospedale Mater Salutis, Via Carlo Ganella, 1, 37045 Legnago, Verona, Italy. 19Department of Medical Oncology, AOU di Modena, Via Emilia Est, 583-585, 41122 Modena, MO, Italy. 20Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli, 40, 47014 Meldola, Italy. 21Department of Medical Oncology, Ospedale degli Infermi di Rimini, Viale L. Settembrini, 2, 47923 Rimini, Italy. 22Department of Medical Oncology, IRCCS Istituto Tumori Bari, Viale Orazio Flacco, 65, 70124 Bari, Italy. 23Department of Medical Oncology, Ospedale A. Perrino di Brindisi, Strada Satale 7 per Mesagne, 72100 Brindisi, Italy. 24Department of Medical Oncology, Casa Sollievo della Sofferenza, Viale Cappuccini, 1, 71013 San Giovanni Rotondo, FG, Italy. 25Department of Medical Oncology, ASST Valdei Olonia, PO Saronne Piazzale Borella 1, 21047 Sarone, Varese, Italy. 26Department of Medical Oncology, Ospedale San Donato, Azienda USL Toscana Sudest Via Pietro Nenni, 20/22, 52100 Arezzo, Italy. 27Department of Medical Oncology, Azienda Ospedaliera ’Ospedali Riuniti Marche Nord’, Piazzale Cinelli, 4, 61121 Pesaro, Italy. 28Department of Medical Oncology, Fondazione Policlinico Universitario “A. Gemelli” - IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Rome, Italy. 29Department of Medical Oncology, A.O.U. Città della Salute e della Scienza di Torino, H Milonette, corso Bramante, 88, 10126 Torino, Italy. 30Division of Medical Oncology, Department of Precision Medicine, University of Campania ‘Luigi Vanvitelli’ - School of Medicine, Via S.Pansini, 5, 80131 Naples, Italy. 31Department of Medical Oncology, P.O. G. Rodolico, Via Plebiscito, 628 Catania, Italy. 32Department of Medical Oncology, AOU Pisana, Polo Oncologico – Osp. S. Chiara, via Roma 67, 56100 Pisa, Italy. 33Department of Hematology-Oncology, University Milan, Milan, Italy.

Received: 24 September 2018 Accepted: 20 March 2019
Published online: 29 March 2019

References
1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27.
2. Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010;13:63–73.
3. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg. 2000;232:362–71.
4. Van Cutsem E, Sagar E, Topal B, et al. Gastric cancer. Lancet. 2016;388:2654–64.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.
6. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
7. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.
8. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (federation francophone de Cancerologie digestive, federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32:3520–6.
9. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
10. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:51–9.
11. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.
12. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;CD004064.
13. Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluorouracil plus leucovorin as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019.
14. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;(8):CD004064.
15. Ajan JA. Recent developments in cytotoxic therapy for advanced gastric or gastroesophageal carcinoma: the phase III trials. Gastrointest Cancer Res. 2007;1:156–21.
16. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450–7.
17. Moehler MH, Ryu M-H, Lee K-W, et al. JAVELIN gastric 100: phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC). J Clin Oncol. 2018;36;TPS195.
18. Di Bartolomeo M, Niger M, Tirino G, et al. Ramucirumab as second-line therapy in metastatic gastric cancer: Real-World data from the RAMoss study. Target Oncol. 2018;13:227–34.
19. Fuchs CS, KS MDB, Lonardi S, Al-Batran S-E, Van Cutsem E, Ison DH, Tabernero J, Chau I, Ducrueux M, Mendez GA, Alvarez AM, Takahari D, Mansoor W, Lacy J, Gorbonova V, Feny D, Ji L, Das M, Shah MA. RAINFALL: a randomized, double-blind, placebo-controlled phase III study of cisplatin (cis) plus capecitabine (cape) or SUFI with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. J Clin Oncol. 2018;36 suppl 4S; abstr 5).
20. Gong J, Hu B, Zhang X, et al. The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma. Oncologist. 2014;19:173–4.
21. Bramhall SR, Hallisyey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002;86:1864–70.
22. Cascini S, Graziano F, Bani S, et al. A phase I study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer. 2001;84:470–4.